Prestige BioPharma Limited (KRX:950210)

Prestige BioPharma Ratios and Metrics

Market cap in millions KRW. Fiscal year is July - June.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 13, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Market Capitalization	188,942	103,966	113,582	137,620	396,635	-
Market Cap Growth	55.01%	-8.47%	-17.47%	-65.30%	-	-
Enterprise Value	222,457	44,042	-6,736	-150,494	-63,944	-
Last Close Price	15720.00	8650.00	9450.00	11450.00	33000.00	-
PE Ratio	43.45	-	6.47	-	-	-
Forward PE	-	12.01	12.01	12.01	-	-
PS Ratio	21.81	150.88	701.81	-	-	-
PB Ratio	0.35	0.20	0.21	0.32	0.69	-
P/TBV Ratio	0.47	0.26	0.28	0.32	0.69	-
EV/Sales Ratio	25.68	63.92	-	-	-	-
Debt / Equity Ratio	0.27	0.20	0.21	0.01	0.01	0.02
Debt / EBITDA Ratio	-	-	9.11	-	-	-
Asset Turnover	0.01	0.00	0	-	-	-
Inventory Turnover	0.08	0.10	0.01	-	-	-
Quick Ratio	1.23	1.57	2.24	7.26	32.70	5.71
Current Ratio	1.38	1.72	2.31	7.46	32.74	5.88
Return on Equity (ROE)	0.04%	-10.38%	-0.59%	-42.08%	-2.07%	-15.29%
Return on Assets (ROA)	-5.17%	-5.35%	0.10%	-13.89%	-3.01%	-6.12%
Return on Capital (ROIC)	-5.90%	-6.07%	0.12%	-15.08%	-3.18%	-7.41%
Return on Capital Employed (ROCE)	-	-	0.20%	-	-	-
Earnings Yield	11.53%	-31.66%	15.47%	-153.65%	-1.86%	-
FCF Yield	-52.38%	-65.49%	-95.65%	-74.36%	-4.13%	-
Buyback Yield / Dilution	-0.07%	-	-	-16.46%	-20.98%	-7.27%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.